Follow-up investigations in cerebrospinal fluid of patients with dementia with Lewy bodies and Alzheimer's disease

Journal of Neural Transmission

Volumn 112, Issue 7, 2005, Pages 933-948

  Mollenhauer, B ^a   Bibl, M ^a   Trenkwalder, C ^a   Stiens, G ^a   Cepek, L ^a   Steinacker, P ^a   Ciesielczyk, B ^a   Neubert, K ^a   Wiltfang, J ^b   Kretzschmar, H A ^c   Poser, S ^a   Otto, M ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

A 40; A 42; Alzheimer's disease; Cerebrospinal fluid; Dementia with lewy bodies; Follow up; Laboratory marker; p tau protein; S 100B protein; Tau protein

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; MARKER; PHOSPHOPROTEIN; PHOSPHORYLATED TAU PROTEIN; PROTEIN S100B; TAU PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DEMENTIA; DISEASE COURSE; DYNAMICS; EVALUATION; FEMALE; FOLLOW UP; HUMAN; LEWY BODY; MALE; PATIENT; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION;

ACETYLCHOLINESTERASE; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BIOLOGICAL MARKERS; DIAGNOSIS, DIFFERENTIAL; ENZYME INHIBITORS; FEMALE; HUMANS; LEWY BODY DISEASE; MALE; MIDDLE AGED; RECEPTORS, N-METHYL-D-ASPARTATE; TAU PROTEINS;

EID: 20944432380     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00702-004-0235-7     Document Type: Article

References (50)

1. Andreasen N, Vanmechelen E, Van de Voorde A, Davidsson P, Hesse C (1998) Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study. J Neurol Neurosurg Psychiatry 64: 298-305
2. (1-42) in Alzheimer disease. Arch Neurol 56: 673-680
3. Aurell A, Rosengren LE, Wikkelsö C, Nordberg G, Haglid KG (1998) The S-100 protein in cerebrospinal fluid: a simple ELISA method. J Neurol Sci 89: 157-164
4. Berger RP, Pierce MC, Wisniewski SR, Adelson PD, Clark RS, Ruppel RA, Kochanek PM (2002) Neuron-specific enolase and S100B in cerebrospinal fluid after severe traumatic brain injury in infants and children. Pediatrics 109: E31
5. Blennow K, Hampel H (2003) CSF markers for incipient Alzheimer's disease. Lancet Neurol 2: 605-613
6. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E (1995) Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 26(3): 231-245
7. Blomberg M, Jensen M, Basum H, Lannfeld L, Wahlund LO (1996) Increasing cerebrospinal fluid tau levels in a subgroup of Alzheimer patients with apolipoprotein E allele ε4 during 14 months follow-up. Neurosci Lett 214: 163-166
8. Buerger K, Zinkowski R, Teipel SJ, Tapiola T, Arai H, Blennow K, Andreasen N, Hofmann-Kiefer K, DeBernardis J, Kerkman D, McCulloch C, Kohnken R, Padberg F, Pirttila T, Schapiro MB, Rapoport SI, Moller HJ, Davies P, Hampel H (2002) Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine231. Arch Neurol 59: 1267-1272
9. Citron M, Westaway D, Xia W, Carlson G, Diehl T, Levesque G, Johnson-Wood K, Lee M, Seubert P, Davis A, Kholodenko D, Motter R, Sherrington R, Perry B, Yao H, Strome R, Lieberburg I, Rommens J, Kim S, Schenk D, Fraser P, St George Hyslop P, Selkoe DJ (1997a) Mutant presinilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice. Nat Med 3: 67-72
10. Citron M, Westaway D, Xia W, Carlson G, Diehl T, Levesque G, Johnson-Wood K, Lee M, Seubert P, Davis A, Kholodenko D, Motter R, Sherrington R, Perry B, Yao H, Strome R, Lieberburg I, Rommens J, Kim S, Schenk D, Fraser P, St George Hyslop P, Selkoe DJ (1997b) Amyloid precursor protein processing and Aβ42 deposition in transgenic mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 94: 1550-1555
11. Frank RA, Galasko D, Hampel H, Hardy J, de Leon MJ, Mehta PD, Rogers J, Siemers E, Trojanowski JQ (2003) Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. Neurobiol Aging 24: 521-536
12. Gaering M, Lynn M, Mirra SS (1999) Neurofibrillary pathology in Alzheimer disease with Lewy-Bodies. Arch Neurol 56: 203-208
13. Galasko D (1998) Cerebrospinal fluid levels of A beta 42 and tau: potential markers of Alzheimer's disease. J Neural Transm [Suppl] 53: 209-221
14. Gomez-Tortosa E, Gonzalo I, Fanjul S, Sainz MJ, Cantarero S, Cemillan C, Yebenes JG, del Ser T (2003) Cerebrospinal fluid markers in dementia with Lewy bodies compared with Alzheimer disease. Arch Neurol 60: 1218-1222
15. Green AJ, Harvey RJ, Thompson EJ, Rossor MN (1997) Increased S100beta in the cerebrospinal fluid of patients with frontotemporal dementia. Neurosci Lett 235: 5-8
16. Hampel H, Mitchell A, Blennow K, Frank RA, Brettschneider S, Weller L, Moller HJ (2004) Core biological marker candidates of Alzheimer's disease - perspectives for diagnosis, prediction of outcome and reflection of biological activity. J Neural Transm 111: 247-272
17. Hampel H, Buerger K, Zinkowski R, Teipel SJ, Goernitz A, Andreasen N, Sjoegren M, DeBernardis J, Kerkman D, Ishiguro K, Ohno H, Vanmechelen E, Vanderstichele H, McCulloch C, Moller HJ, Davies P, Blennow K (2004) Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease. Arch Gen Psychiatry 61: 95-102
18. Hansen LA, Samuel W (1994) Criteria for Alzheimer's disease and the nosology of dementia with Lewy bodies. Neurology 48: 126-132
19. Harrington CR, Perry RH, Perry EK, Hurt J, McKeith IG, Roth M, Wischik CM (1994) Senile dementia of Lewy body type and Alzheimer type are biochemically distinct in terms of paired helical filaments and hyperphosphorylated tau protein. Dementia 5: 215-222
20. Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, De Deyn PP, Bancher C, Cras P, Wiltfang J, Mehta PD, Iqbal K, Pottel H, Vanmechelen E, Vanderstichele H (1999) Improved discrimination of AD-patients using β-amyloid (1-42) and tau levels in CSF. Neurology 52: 1555-1562
21. Iseki E, Takayama N, Marui W, Ueda K, Kosaka K (2002) Relationship in the formation process between neurofibrillary tangles and Lewy bodies in the hippocampus of dementia with Lewy bodies brains. J Neurol Sci 195: 85-91
22. Iseki E, Togo T, Suzuki K, Katsuse O, Marui W, de Silva R, et al. (2003) Dementia with Lewy bodies from the perspective of tauopathy. Acta Neuropathol 105: 265-270
23. Isoe K, Urakami K, Shimomura T, Wakutani Y, Ji Y, Adachi Y, Takahashi K (1996) Tau proteins in cerebrospinal fluid from patients with Alzheimer's disease: a longitudinal study. Dementia 7(3): 175-176
24. Kanai M, Matsubara E, Isoe K, Urakami K, Nakashima K, Arai H, Sasaki H, Abe K, Iwatsubo T, Kosaka T, Watanabe M, Tomidokoro Y, Shizuka M, Mizushima K, Nakamura T, Igeta Y, Ikeda Y, Amari M, Kawarabayashi T, Ishiguro K, Harigaya Y, Wakabayashi K, Okamoto K, Hirai S, Shoji M (1998) Longitudinal study of cerebrospinal fluid levels of tau, Aβ1-40, and Ab1-42(43) in Alzheimer's disease: a study in Japan. Ann Neurol 44: 17-26
25. Kanai M, Shizuka M, Urakami K, Matsubara E, Harigaya Y, Okimoto K, Shoji M (1999) Apolipoprotein E4 accelerates dementia and increases cerebrospinal fluid tau levels in Alzheimer's disease. Neurosci Lett 267: 65-68
26. Kanemaru K, Kameda N, Yamanouchi H (2000) Decreased CSF amyloid β42 and normal tau levels in dementia with Lewy bodies. Neurology 54: 1875-1876
27. Kaufer DI (2002) Pharmacologic therapy of dementia with Lewy bodies. J Geriatr Psychiatry Neurol 15(4): 224-232
28. Lippa CF, Ozawa K, Mann DM, Ishii K, Smith TW, Arawaka S, Mori H (1999) Deposition of beta-aymloid subtypes 40 and 42 differentiates dementia with Lewy bodies from Alzheimer disease. Arch Neurol 56: 1111-1118
29. Maddalena A, Papassotiropoulos A, Müller-Tillmanns B, Jung HH, Hegi T, Nitsch RM, Hock C (2003) Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to β-amyloid peptide 42. Arch Neurol 60: 1202-1206
30. Maeck L, Meller J, Otto M, Stiens G, Wiltfang J, Stoppe G (2002) Abeta peptide 1-42, Tau protein and S-100B protein level in cerebrospinal fluid of three patients with primary progressive aphasia. Neurosci Lett 333: 33-36
31. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN, Ballard C, de Vos RA, Wilcock GK, Jellinger KA, Perry RH (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47: 1113-1124
32. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 34(7): 939-944
33. Mehta PD, Pirttila T, Patrick BA, Barshatzky M, Mehta SP (2001) Amyloid β protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease. Neurosci Lett 304: 102-106
34. Merdes AR, Hansen LA, Jeste DV, Galasko D, Hofstetter CR, Ho GJ, Thal LJ, Corey-Bloom J (2003) Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology 60: 1586-1590
35. Otto M, Stein H, Szudra A, Zerr I, Bodemer M, Gefeller O, Poser S, Kretzschmar HA, Mader M, Weber T (1997) S-100 protein concentration in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. J Neurol 244: 566-570
36. Otto M, Wiltfang J, Cepek L, Neumann M, Mollenhauer B, Steinacker P, Ciesielczyk B, Schulz-Schaeffer W, Kretzschmar HA, Poser S (2002) Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 58: 192-197
37. Parnetti L, Lanari A, Amici S, Gallai V, Vanmechelen E, Hulstaert F (2001) CSF phosphorylated tau is a possibile marker for discriminating Alzheimer's disease from dementia with Lewy-Bodies. Neurol Sci 22: 77-78
38. Parnetti L, Amici S, Lanari A, Romani C, Antognelli C, Andreasen N, Minthon L, Davidsson P, Pottel H, Blennow K, Gallai V (2002) Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors. Neurol Sci 23: S95-S96
39. Perry EK, Haroutunian V, Davis KL, Levy R, Lantos P, Eagger S, Honavar M, Dean A, Griffiths M, McKeith IG, et al. (1994) Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease. Neuroreport 5(7): 747-749
40. Stefanova E, Blennow K, Almkvist O, Hellstrom-Lindahl E, Nordberg A (2003) Cerebral glucose metabolism, cerebrospinal fluid-beta-amyloid1-42 (CSF-Abeta42), tau and apolipoprotein E genotype in long-term rivastigmine and tacrine treated Alzheimer disease (AD) patients. Neurosci Lett 338(2): 159-163
41. Sobow T, Flirski M, Liberski PP (2004) Amyloid-beta and tau proteins as biochemical markers of Alzheimer's disease. Acta Neurobiol Exp 64: 53-70
42. Sunderland T, Wolozin B, Galasko D, Levy J, Dukoff R, Bahro M, Lasser R, Motter R, Lehtimäki T, Seubert P (1999) Longitudinal stability of tau levels in Alzheimer patients. Biol Psychiatry 46: 750-755
43. Sunderland T, Linker G, Mirza N, Putnam KT, Friedman DL, Kimmel LH, Bergeson J, Manetti GJ, Zimmermann M, Tang B, Bartko JJ, Cohen RM (2003) Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 289(16): 2094-2103
44. Sussmuth SD, Tumani H, Ecker D, Ludolph AC (2003) Amyotrophic lateral sclerosis: disease stage related changes of tau protein and S100 beta in cerebrospinal fluid and creatine kinase in serum. Neurosci Lett 353: 57-60
45. Tapiola T, Pirttilä T, Mikkonen M, Mehta PD, Alafuzoff I, Koivisto K, Soininen H (2000) Three-year follow-up cerebrospinal fluid tau, β-Amyloid 42 and 40 concentrations in Alzheimer's disease. Neurosci Lett 280: 119-122
46. Tato RE, Frank A, Henanz A (1995) Tau protein concentration in cerebrospinal fluid of patients with dementia of the Alzheimer type. J Neurol Neurosurg Psychiatry 59: 280-283
47. Tschampa HJ, Schulz-Schaeffer W, Wiltfang J, Poser S, Otto M, Neumann M, Kretzschmar HA (2001) Decreased CSF amyloid 42 and normal tau levels in dementia with Lewy bodies. Neurology 56: 576
48. Verbeek MM, De Jong D, Kremer HP (2003) Brain-specific proteins in cerebrospinal fluid for the diagnosis of neurodegenerative diseases. Ann Clin Biochem 40: 25-40
49. Wahlund LO, Blennow K (2003) Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients. Neurosci Lett 339: 99-102
50. Wesnes KA, McKeith IG, Ferrara R, Emre M, Del Ser T, Spano PF, Cicin-Sain A, Anand R, Spiegel R (2002) Effect of Rivastigmine on cognitive function in dementia with Lewy bodies: a randomised placebo-controlled international study using the cognitive drug research computerised assessment system. Dement Geriatr Cogn Disord 13: 183-192